News | April 28, 2023
Yasmin and Mirena to take back seat from Bayer’s future drug strategy, says GlobalData
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
The funding will be used to expand the product line for remote patient monitoring and to scale the business across Asia and Africa
New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists
Biocon Biologics Limited will have access to 100 million doses of vaccines annually together with the distribution rights to Serum's Vaccine portfolio
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
The burden of treating chronic wounds is growing rapidly due to increasing health care costs
The acquisition is a crucial step in LTS' strategy to broaden its portfolio of drug delivery platforms.
Fully equipped labs with 75-member team set-up and made operational in <100 days
Aji Bio-Pharma has six fill finish lines located in San Diego, including a new line
Subscribe To Our Newsletter & Stay Updated
